Close
CDMO Safety Testing 2026
Novotech

Lupin Announces Final FDA Approval of Generic Hyzaar® and Cozaar

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Aragen Backs Renaissance Rare Disease Therapy Launch

Contract research, development, and manufacturing organization (CRDMO) Aragen has...

Eli Lilly and Haisco Pharmaceutical Enter $3Billion+ Deal

Eli Lilly has entered into a multi-program collaboration with...

Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi

Eli Lilly and Company and Hanmi Pharm have officially...
- Advertisement -

Pharma Major, Lupin Limited announced that its U.S subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has been granted final approval for the company’s generic versions of Merck’s antihypertensive agents *Hyzaar® (hydrochlorothiazide; losartan potassium) and *Cozaar® (losartan potassium) by the U.S. Food and Drug Administration.

The brand products had combined annual sales of approximately $1.6 billion in the United States, based on IMS sales data for the 12 months ended June 2010.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Latest stories

Related stories

Aragen Backs Renaissance Rare Disease Therapy Launch

Contract research, development, and manufacturing organization (CRDMO) Aragen has...

Eli Lilly and Haisco Pharmaceutical Enter $3Billion+ Deal

Eli Lilly has entered into a multi-program collaboration with...

Lilly Signs $1.26bn Sonefpeglutide Licensing Deal with Hanmi

Eli Lilly and Company and Hanmi Pharm have officially...

Pharmacogenomics in 2026: From Research Concept to Clinical Workflow

Pharmacogenomics has moved well beyond the research phase. In...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »